Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions using superficial radiotherapy (SRT and IG-SRT). The SRTS news page on Stock Titan aggregates company announcements, press releases and market updates so readers can follow how Sensus’ technology, reimbursement environment and commercial activities evolve over time.
Recent news highlights include recognition of Sensus Healthcare as a global pioneer in non-invasive treatments for skin cancer and keloids, updates on clinical evidence for its SRT systems, and developments in reimbursement policy. The company has reported that the Centers for Medicare & Medicaid Services established dedicated CPT codes specific to superficial radiotherapy for non-melanoma skin cancer, which Sensus describes as a pivotal moment for its platform and strategy. News items also cover growth in treatment volumes under its Fair Deal Agreement program and shipments of SRT systems to both U.S. and international customers.
Investors and healthcare professionals can use this news feed to track quarterly financial results, board and governance changes, conference participation, and recognition such as Sensus Healthcare’s inclusion in TIME’s America’s Growth Leaders of 2026 ranking. Clinical and scientific updates, including published studies on the use of SRT for keloids, provide additional context on how the company’s technology is being used in practice.
By reviewing the SRTS news stream regularly, readers can see how Sensus Healthcare communicates its progress in radiation oncology technology, reimbursement milestones, commercial expansion and clinical validation of its superficial radiotherapy solutions.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, announces its upcoming Third Quarter 2024 financial results conference call scheduled for November 14, 2024, at 4:30 p.m. Eastern time. Management will discuss Q3 2024 financial results, provide business updates, and review recent and upcoming milestones. The call will be accessible via pre-registration or direct dial-in, with a replay available until December 14, 2024. A webcast will also be available through the company's website.
Sensus Healthcare (Nasdaq: SRTS) has shipped an SRT system to Providence Swedish Hospital in Seattle, marking its latest success in expanding to community hospital oncology departments. The sale highlights growing interest in superficial radiotherapy (SRT) for treating non-melanoma skin cancer and keloids on an outpatient basis.
Dr. Christopher Loiselle, Medical Director of Radiation Oncology at Swedish Cancer Institute, praised the SRT system as state-of-the-art for treating skin cancers and other superficial conditions. Joe Sardano, CEO of Sensus Healthcare, expressed delight in Providence Swedish Hospital's recognition of SRT benefits and noted increasing inquiries from hospitals nationwide about offering non-invasive skin cancer treatments.
Sensus Healthcare (SRTS) reported strong Q2 2024 financial results, with revenues doubling to $9.2 million compared to Q4 2023. The company achieved net income of $1.6 million ($0.10 per diluted share) and positive Adjusted EBITDA of $2.1 million. Key highlights include:
- Shipped 23 systems, including 3 SRT-100 units to Asia
- Signed 15 'Fair Deal Agreements' for SRT-100 Vision units
- Ended Q2 with $19 million in cash and no debt
- Accounts receivable increased to $18.3 million
The company's growth was driven by higher superficial radiotherapy unit sales and international expansion efforts, particularly in Asia. Management expects the Fair Deal Agreement program to generate recurring revenue starting in 2025.
Sensus Healthcare (Nasdaq: SRTS) has announced a conference call scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time to discuss its second quarter 2024 financial results and provide a business update. The company, which specializes in non-invasive treatments for oncological and non-oncological conditions, encourages participants to pre-register for the call. Those unable to pre-register can dial in directly. The call will also be webcast live and accessible through the company's website. A telephone replay will be available until September 8th, and an archived webcast will be accessible in the Investor Relations section of the website.
Sensus Healthcare (Nasdaq: SRTS), a medical device company specializing in non-invasive treatments for oncological and non-oncological conditions, has announced its upcoming second quarter 2024 financial results and business update conference call. The call is scheduled for Thursday, August 8, 2024, at 4:30 p.m. Eastern time.
Key points:
- Management will discuss Q2 2024 financial results
- A business update and discussion on recent and upcoming milestones will be provided
- Participants can pre-register for the call or dial in directly
- A webcast will be available on the company's Investor Relations website
- A telephone replay will be accessible until September 8th
Sensus Healthcare reported a strong first-quarter financial performance with revenues up over three-fold compared to the previous year. Revenues were $10.7 million, net income was $2.3 million, and adjusted EBITDA was $3.0 million. The company launched a recurring revenue program, the 'Fair Deal Agreement', to complement its fair market value lease program. Sensus Healthcare showcased its products at key industry events and announced significant sales and developments, including a U.S. patent for SRT-100 Vision System and international sales.
Sensus Healthcare, Inc. announces the sale of an SRT-100 system to the Veterinary Specialist Referral Center in Tel Aviv, marking the first veterinary commercial sale of the device outside the U.S. This system will provide gentler radiotherapy to treat tumors in dogs and cats. The Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel, employing over 20 specialists and 30 veterinary technicians. The SRT-100 system has previously been acquired by Colorado State University for treating companion animals and conducting studies on equine ophthalmic tumors.
Sensus Healthcare, Inc. announces the sale of the first SRT-100 Vision™ system in Asia to Far Eastern Memorial Hospital in Taiwan. The hospital plans to conduct research on new indications for the system, potentially leading to global label expansion. The company is optimistic about future sales in the region and emphasizes the importance of this sale. The SRT-100 Vision system utilizes image-guided ultrasound technology and has seen recent enhancements for improved clinical outcomes. Additionally, Sensus Healthcare will host a conference call on May 9, 2024, to discuss first-quarter financial results and provide business updates.
Summary not available.
Summary not available.